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Regarding “Endovenous laser treatment of the short
saphenous vein: Efficacy and complications”
I enjoyed the excellent article of Gibson et al,1 and have a
question about the details of endovenous laser treatment (EVLT)
with respect to the Giacomini vein termination. The recurrence
rate of the small saphenous vein (SSV) is generally more than 30%.2
The point where the Giacomini vein connects to the SSV differs
among individual patients, ranging from immediately subfascial
(Fig, B) to deep near the saphenopopliteal junction (SPJ; Fig A).3
By using EVLT beginning distal to the termination of the Giaco-
mini vein, in order to preserve flow from the Giacomini vein to the
SSV in type B patients, a long SSV stump is left, which might cause
treatment failure and recurrence. Do the authors always start
EVLT from distal to the termination of the Giacomini vein when
treating type B patients? How do they perform EVLT in patients
with reflux in both the SSV trunk and Giacomini vein?
We prefer to start EVLT from 1 cm to 1.5 cm distal to the SPJ
to avoid leaving a long residual SSV stump. Therefore, for almost
all patients, we conduct EVLT proximal to the site where the
Giacomini vein is drained. Contrary to the variability of the Gia-
comini vein termination, in case of the gastrocnemius vein termi-
nating at the SSV, it terminated almost always just distal of the SPJ.
Thus, we start EVLT from 1 to 1.5 cm distal to the site where the
gastrocnemius vein terminated into the SSV to maintain the nor-
mal venous flow of the gastrocnemius vein.
Our clinical experience with more than 4600 limbs (including
1086 SSVs) treated with EVLT spans 5 years, with all patients
undergoing post-EVLT duplex scans at multiple time periods. Our
routine follow-up duplex scan schedule is 2 days, 1 week, 1 month,
3 months, 6 months, thereafter annually. Surprisingly, we have
never seen a deep vein thrombosis in any of our patients.
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Regarding “Duplex surveillance following carotid
surgery: effect of management policy”
I refer to the study by Ballotta and colleagues, which described
the outcome of 599 patients following carotid endarterectomy.1 The
authors report excellent perioperative results and also examine
the outcome of follow-up duplex surveillance. The authors
conclude that their findings strongly support the value of duplex
surveillance every 6 months after carotid surgery. The interpreta-
tion of this study needs to take into account controversies regard-
ing managing asymptomatic carotid artery disease.2,3 An imaging
finding is primarily of value if it alters the clinical management of
the patient. The potential findings from surveillance after carotid
surgery include ipsilateral restenosis or contralateral progression of
stenosis. While this and other studies indicate that both these
problems can be easily and commonly identified by duplex surveil-
lance, the management of them remains controversial.4 Ipsilateral
restenosis particularly, if developing within the first year following
surgery, is believed to have a benign natural history and, therefore,
many clinicians treat such lesions medically.4 Similarly, the man-
agement of asymptomatic carotid stenosis also remains controver-
sial with meta-analyses suggesting significant but small reduction
in stroke incidence based on interventional treatment of all patients
with asymptomatic carotid stenosis.2,3 Only two of the patients in
the present study suffered a stroke associated with progression of
Endovenous laser therapy of small saphenous vein (SSV). A, The
Giacomini vein connects to the SSV near saphenopopliteal junc-
tion. B, The Giacomini vein connects to the SSV at immediate
subfascial level, leaving a long stump. PV, Popliteal vein; SF,
superficial fascia; DF, deep fascia.
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stenosis despite a conservative approach to asymptomatic carotid
disease, in keeping with previous studies.1,4 Following a transient
ischemic attack, patients require duplex scanning after the event to
direct their management. Thus, for patients in whom a conserva-
tive approach is to be applied to asymptomatic restenosis or pro-
gression of contralateral disease, the value of duplex surveillance is
limited to research and audit. To clearly demonstrate a value of
duplex surveillance following carotid surgery would require an
appropriately powered randomized trial. Possibly more useful than
duplex surveillance might be the identification of biomarkers,
genetic markers or new imaging techniques that better identify
presently asymptomatic patients likely to experience a stroke.5,6
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Reply
We appreciate professor Golledge’s comments on one of the
more controversial issues concerning patients who undergo carotid
surgery—ie, the utility of ultrasound surveillance to manage the
progression of contralateral asymptomatic carotid disease.1
Golledge asserts that “an imaging finding is primarily of value
if it alters the clinical management of the patient.” Therefore,
taking Golledge’s words literally, because diabetic patients (being
at high vascular risk, according to current guidelines) are given
antiplatelet therapy, they should not have duplex ultrasonography
(DUS) until they suffer a stroke or other cardiovascular event,
because it is only then that a change of treatment would be
recommended—a bit late, in our opinion. According to the results
of the major randomized clinical trials, DUS follow-up would at
least pinpoint patients progressing to severe asymptomatic carotid
disease and likely to benefit from carotid endarterectomy. Contrar-
ily to the previous statement, Golledge himself admits that DUS
can noninvasively detect patients with complications potentially
hazardous to their health if not properly treated.
Golledge says that “ipsilateral restenosis. . .is believed to have a
benign natural history and therefore many clinicians treat such lesions
medically.”2 But how do we identify ipsilateral restenosis without
proper imaging? And how can the benign nature of such lesion be
established without a proper follow-up, including clinical assessment
and instrumental evaluation (DUS is the cheapest and safest method
available)?
The meta-analyses that Golledge mentions3,4 demonstrate that,
in expert hands, patients (especially men) with stenosis greater than
60% clearly benefit from carotid endarterectomy; considering the
burden of stroke on a patient and the community, we are sure
Golledge would agree on the merits of avoiding even a single stroke.
We agree that an appropriately powered randomized trial
would be preferable to our large but single-center study, and we
would be happy to collaborate with professor Golledge to set up
such a trial. Every patient deserves the best possible management,
wherever they live, which is why DUS (which is readily available
everywhere, cheap, and noninvasive) is useful in such a context (the
same can be hardly be said for the high-resolution, ultrasmall,
superparamagnetic iron oxide–enhanced magnetic resonance im-
aging5). We know of no specific biomarkers or genetic markers
capable of reliably identifying asymptomatic patients likely to
experience a stroke: C-reactive protein is one of many biomarkers
being studied as a predictor of cardiovascular events in patients
with carotid stenosis6, but it is aspecific for stroke, and the research
has been conducted on patients taking platelet inhibitors and/or
statins, which influence not only the occurrence of cardiocerebro-
vascular events but also the levels of acute-phase inflammatory
parameters such as C-reactive protein.
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Regarding “EXCLUDER trial events are excluded
from EXCLUDER trial report”
We read with interest the article of Peterson et al,1 which
reported 5-year data from a controlled trial of the EXCLUDER
device for endovascular repair (EVAR) of abdominal aortic aneu-
rysms but are concerned that their conclusions are not supported
by the presented data. The study was nonrandomized, as the
investigators state, but there are other large sources of confusion.
For example, of 235 patients selected for EVAR, only 128 patients
are included with no explanation of what happened to the remain-
ing 107 patients. Furthermore, though the investigator’s defini-
tion of adverse events is given in text, there is no description of
what these events actually were, who adjudicated them, or whether
they were blinded. The authors show that nearly 70% of patients
treated with open repair had a major adverse event within 30 days,
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